ATE386537T1 - Verfahren zur modulierung von t-zellreaktionen durch manipulation einer gemeinsamen zytokinrezeptor-gammakette - Google Patents

Verfahren zur modulierung von t-zellreaktionen durch manipulation einer gemeinsamen zytokinrezeptor-gammakette

Info

Publication number
ATE386537T1
ATE386537T1 AT95924766T AT95924766T ATE386537T1 AT E386537 T1 ATE386537 T1 AT E386537T1 AT 95924766 T AT95924766 T AT 95924766T AT 95924766 T AT95924766 T AT 95924766T AT E386537 T1 ATE386537 T1 AT E386537T1
Authority
AT
Austria
Prior art keywords
gamma chain
receptor
cytokine receptor
cell
interleukin
Prior art date
Application number
AT95924766T
Other languages
English (en)
Inventor
Vassiliki Boussiotis
Lee Nadler
Original Assignee
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc filed Critical Dana Farber Cancer Inst Inc
Application granted granted Critical
Publication of ATE386537T1 publication Critical patent/ATE386537T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2046—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT95924766T 1994-07-01 1995-06-30 Verfahren zur modulierung von t-zellreaktionen durch manipulation einer gemeinsamen zytokinrezeptor-gammakette ATE386537T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/270,152 US6576236B1 (en) 1994-07-01 1994-07-01 Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain

Publications (1)

Publication Number Publication Date
ATE386537T1 true ATE386537T1 (de) 2008-03-15

Family

ID=23030131

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95924766T ATE386537T1 (de) 1994-07-01 1995-06-30 Verfahren zur modulierung von t-zellreaktionen durch manipulation einer gemeinsamen zytokinrezeptor-gammakette

Country Status (10)

Country Link
US (2) US6576236B1 (de)
EP (2) EP0768890B1 (de)
JP (2) JPH10502372A (de)
AT (1) ATE386537T1 (de)
AU (1) AU2915295A (de)
CA (1) CA2194239A1 (de)
DE (1) DE69535713T2 (de)
DK (1) DK0768890T3 (de)
ES (1) ES2299174T3 (de)
WO (1) WO1996001122A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3362192B2 (ja) * 1994-12-06 2003-01-07 味の素株式会社 検査方法及び検査薬
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
EP0824594B1 (de) * 1995-05-04 2005-04-06 The United States of America as Representend by The Secretary of the Navy Verbesserte verfahren zur transfektion der t-zellen
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
EP0773313B1 (de) * 1995-10-11 2000-08-09 ARTEVA TECHNOLOGIES S.à.r.l. Schwerentflammbare Sicherheitsgurte enthaltend phosphor-modifizierte Polyesterfasern
FR2745185B1 (fr) * 1996-02-28 1998-05-15 Sanofi Sa Utilisation de l'il-7 dans le traitement des maladies auto-immunes, en particulier le diabete mellitus insulinodependant
US6316257B1 (en) * 1996-03-04 2001-11-13 Targeted Genetics Corporation Modified rapid expansion methods (“modified-REM”) for in vitro propagation of T lymphocytes
US5807743A (en) * 1996-12-03 1998-09-15 Ribozyme Pharmaceuticals, Inc. Interleukin-2 receptor gamma-chain ribozymes
WO1998034631A1 (en) * 1997-02-07 1998-08-13 Thomas Jefferson University Peptide mimetics of the cytokine receptor gamma chain
DE19721099C2 (de) 1997-05-20 1999-12-02 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
AU2001234784A1 (en) * 2000-02-04 2001-08-14 Bioseek Compositions and methods for reducing autoimmunity
JP2004533226A (ja) * 2001-04-02 2004-11-04 ワイス Ｂ７−４に対するｐｄ−１、ａレセプター、およびその使用
PL1663197T3 (pl) 2003-09-09 2008-09-30 Biogen Idec Int Gmbh Zastosowanie pochodnych kwasu fumarowego do leczenia niewydolności serca oraz astmy
JP2009527500A (ja) * 2006-02-16 2009-07-30 ナセント・バイオロジックス・インコーポレイテッド 免疫機能を改善するための方法および哺乳動物対象における疾患の防止または処置のための方法
LT2653873T (lt) 2007-02-08 2022-10-10 Biogen Ma Inc. Kompozicijos ir naudojimas, skirti išsėtinei sklerozei gydyti
WO2014209855A1 (en) * 2013-06-24 2014-12-31 Anthrogenesis Corporation Methods of expanding t cells
AU2020214812A1 (en) 2019-02-01 2021-09-23 Regeneron Pharmaceuticals, Inc. Anti-IL2 receptor gamma antigen-binding proteins

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (de) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimäre Rezeptoren durch Verbindung und Expression von DNS
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
WO1987002671A1 (en) 1985-11-01 1987-05-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
US5017691A (en) * 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0768377A1 (de) 1988-09-02 1997-04-16 Protein Engineering Corporation Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
IL92382A (en) 1988-11-23 1994-12-29 Univ Michigan Use of a ligand specific for CD28 in the manufacture of medicament
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
EP0441917B1 (de) * 1989-07-25 1996-05-01 The Regents Of The University Of Minnesota Konjugate von "pokeweed" antiviralem protein und monoklonalen antikörpern
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
JPH06508511A (ja) 1990-07-10 1994-09-29 ケンブリッジ　アンティボディー　テクノロジー　リミティド 特異的な結合ペアーの構成員の製造方法
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5229115A (en) * 1990-07-26 1993-07-20 Immunex Corporation Adoptive immunotherapy with interleukin-7
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5612205A (en) 1990-08-29 1997-03-18 Genpharm International, Incorporated Homologous recombination in mammalian cells
EP0552243B1 (de) * 1990-09-06 1996-11-27 Schering Corporation Verwendung von interleukin-4 zur behandlung der festen tumoren
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
DK1279731T3 (da) 1991-03-01 2007-09-24 Dyax Corp Fremgangsmåde til udvikling af bindende miniproteiner
US5474769A (en) * 1991-03-08 1995-12-12 Sterling Winthrop Inc. Treatment of microbial infection by monocyte stimulation with interleukin-7
DK1471142T3 (da) 1991-04-10 2009-03-09 Scripps Research Inst Heterodimere receptor-biblioteker under anvendelse af fagemider
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
AU687755B2 (en) * 1992-08-21 1998-03-05 Genentech Inc. Method for treating an LFA-1-mediated disorder
WO1994010300A1 (en) 1992-10-30 1994-05-11 The General Hospital Corporation Interaction trap system for isolating novel proteins
EP0621338A3 (de) * 1993-04-21 1997-10-29 Ajinomoto Kk Die Interleukin-2 Antwort blockierende Immunsuppressor.
US20020127201A1 (en) * 1994-07-01 2002-09-12 Dana-Farber Cancer Institute. Methods for inhibiting T cell responses by manipulating a common cytokine receptor gamma-chain

Also Published As

Publication number Publication date
US6576236B1 (en) 2003-06-10
AU2915295A (en) 1996-01-25
WO1996001122A1 (en) 1996-01-18
EP0768890A1 (de) 1997-04-23
DE69535713D1 (de) 2008-04-03
CA2194239A1 (en) 1996-01-18
EP0768890B1 (de) 2008-02-20
DE69535713T2 (de) 2009-03-19
JPH10502372A (ja) 1998-03-03
US20040037808A1 (en) 2004-02-26
DK0768890T3 (da) 2008-06-09
ES2299174T3 (es) 2008-05-16
EP1958966A2 (de) 2008-08-20
JP2007112815A (ja) 2007-05-10

Similar Documents

Publication Publication Date Title
ATE386537T1 (de) Verfahren zur modulierung von t-zellreaktionen durch manipulation einer gemeinsamen zytokinrezeptor-gammakette
ATE47866T1 (de) Copolymere auf basis von maleinsaeureanhydrid und alpha, beta-ungesaettigten verbindungen, ein verfahren zu ihrer herstellung und ihre verwendung als paraffininhibitoren.
ATE201236T1 (de) Zur ortsspezifischen rekomination fähige agrobakterium stämme
DK0597960T3 (da) Behandling af cellepopulationer
ATE25085T1 (de) Neue lichtstabilisatoren fuer polymere.
DK375283D0 (da) Dna-sekvenser, rekombinations-dna-molekyler samt fremgangsmader til fremstilling af kvaegvaeksthormonlignende polypeptider
ATE266671T1 (de) Nukleinsäuresynthese unter verwendung von mittels licht abspaltbaren schutzgruppen
DK0414475T3 (da) Fremgangsmåder til dyrkning af HCV i B- eller T-lymfocyt-cellelinier
DE3671640D1 (de) Kationische emulsionen von bitumen-polymerartigen bituminoesen bindemitteln und kationisches emulgiersystem, unter anderem verwendbar zur erhaltung derselben.
DE3583189D1 (de) Carbazole und ihre verwendung als photoinitiatoren von photopolymerisierbaren, ungesaettigten verbindungen.
ATA901987A (de) Vorrichtung zur erzeugung von gas aus festen brennstoffen
DE69314024D1 (de) NEUE GABAa-REZEPTORSUBTYPEN UND VERFAHREN ZUM SCREENING VON ARZNEIMITTELVERBINDUNGEN UNTER VERWENDUNG VON GABAa-REZEPTORSUBTYPEN BINDENDE IMIDAZOCHINOXALINE UND PYRROLOPYRIMIDINE
DE3851925D1 (de) Alkylaminalkoxyphenyl-Derivate, Verfahren zur Verwendung und sie enthaltende Zusammensetzungen.
DE3576361D1 (de) Rekombinante dna, damit transformierter mikroorganismus, und verfahren zur herstellung von menschlicher cu-zn superoxiddismutase unter verwendung des transformierten mikroorganismus.
DE3485319D1 (de) Rekombinante dns, diese rekombinante dns enthaltende bakterien, und verfahren zur herstellung von l-threonin oder l-isoleucin unter verwendung dieser bakterien.
ATA171787A (de) Heizanlage zum verbrennen von festen brennstoffen
DE69227589D1 (de) Ecdysteroid-abhängige gen regulierung in säugetier-zellen
NO854710L (no) Fremgangsmåte for kontroll og styring av injeksjonssonens utstrekning ved jetinjisering av herdbart bindemiddel i jordarter, samt anordning for gjennomføring av fremgangsmåten.
ATE312175T1 (de) Verfahren zur erhöhung der überlebensrate von neuronen und dafür verwendbare mittel
DE59001452D1 (de) Verfahren zur optimierung der verbrennung von kraftstoffen bei minimaler co-emission und vorrichtung zur durchfuehrung des verfahrens.
ATE45746T1 (de) Substituierte o-acyl-glycosylamide, verfahren zu ihrer herstellung sowie ihre verwendung.
DE3851493D1 (de) Methode und anlage zur erzeugung von lichtstrahlung aus freiem positronium.
ATE153997T1 (de) Entfärbung von alkylierten diarylaminen
BR9604947A (pt) Genes que codificam polipept¡deos (lsirf) fatores reguladores de interferon linfoc¡tico
AT375954B (de) Verfahren zur herstellung von selbstvernetzenden, kathodisch abscheidbaren etl-bindemitteln auf basis modifizierter phenol-novolake

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties